Clinical Trial Update: A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluating how the body processes a single oral dose of VX-993 labeled with carbon-14 (14C-VX-993). The study has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• VX-993

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Pain | Phase 1 | Status: COMPLETED